U.S. PRE-MARKET MOVERS: ANR CLD CLVS EXEL IMGN JNPR KTOS MRTX

Equity movers in early trading, with shrs traded pre-mkt: Advancers:

  • ONTY +29.5% (1558.1k); ONT-380 Data Backs Plans to Initiate Phase 2 Trial
  • OMG +27.9% (30k); To Be Bought by Apollo for $34-Shr, Premium 28%
  • IMGN +19.4% (57.2k); Ovarian Cancer Drug Has 53% Response Rate in Study
  • VBLT +10.7% (268.2k); Positive Ovarian Cancer Data
  • EXEL +12.1% (119.3k); Positive Melanoma Data at ASCO
  • ANR +10.6% (114.7k); Assumed Neutral at Goldman
  • TGTX +8% (11.1k); Presented at ASCO
  • SYN +7.9% (37.1k); New Outperform at William Blair 0
  • HALO +7.2% (14k); Drug Data Suggest PFS, OS Benefit in Pancreatic Cancer
  • KTOS +6.9% (2.9k); Ultra Electronics to Buy Kratos’ EPD Unit for Up to $265m Cash
  • BIOC +6.5% (20.5k); Granted U.S. Patent for Blood Collection Tube
  • CLDN +6.1% (31.7k); To Seek Purchase or Partnership; Cleveland Named CEO
  • LIFE +5.9% (1.4k); New Buy at Citi, New Outperform at BMO Capital, William Blair, New Overweight at JPMorgan
  • ADAP +5.5% (12.8k); New Buy at Guggenheim; New Outperform at Cowen, Leerink
  • CLCD +5.3% (2.7k); New Buy at Ladenburg Thalmann, Stifel; New Outperform at William Blair, New Overweight at Piper Jaffray
  • HERO +5.1% (4.1k); Withdraws Termination Notice for Hercules 261 Contract 0
  • ALTR +4.8% (567.8k); Intel To Buy Altera For $54-Shr
  • NWBO +4.7% (4.3k); Presented at ASCO
  • IMMU +4.7% (6.3k); Says 2 Complete Responses Seen in TNBC Study
  • JUNO +4.5% (4.8k); JCAR015 Has 87% Complete Remission in Phase 1 ALL Study
  • ADXS +3.3% (14.6k); Says FDA OKs Phase 2 study of ADXS-HPV With Incyte Drug
Decliners:
  • MRTX -20.9% (1.2k); Downgraded at Brean Capital
  • CLVS -8% (20.7k); JPMorgan Calls Rociletinib Data “So-So”
  • CLD -5.2% (4.7k); Assumed Sell at Goldman
  • JNPR -1.4% (3.5k); Downgraded at Mkm Partners
May Move:
  • AAPL: Is Considering Sale of Yen Bonds ’in Coming Days’
  • ACAT: Downgraded at BMO Capital
  • ACHN: Holder Point72 Reports 5% Passive Stake
  • ACI: Assumed Neutral at Goldman
  • ACW: NHTSA Closes Investigation Into Accuride Steel Wheels
  • AEGR: Holder Stonepine Reports 5.2% Passive Stake
  • AFAM: Files $300M Mixed Securities Shelf
  • AFMD: New Outperform at Oppenheimer
  • AGEN: Says Prophage Improves PFS, Median OS in Brain Cancer
  • AIR: To Buy 4.19M of Its Shrs at $31.90/Shr in Tender Offer
  • ALXN: Alexion Sees Synageva Deal Closing in Mid 2015
  • AMC: Received Civil Investigative Demand
  • ANAC: Names Graeme Bell as New Evp, CFO
  • ARQL: Names Robert J. Weiskopf as CFO
  • AST: Data Shows Prolonged Relapse-Free Survival
  • ATLS: New Equal-Weight at Morgan Stanley
  • ATRS: Sees Starting Trial in 3Q 2015
  • AWI: New Hold at Vertical Research
  • AXP: Bid for Antitrust Court Ruling Delay to Be Heard June 16
  • AZN: Arimidex May Reduce Risk of Breast Cancer
  • BAMM: 1Q Same-Store Sales Down 0.9% :Bamm US
  • BBEP: New Equal-Weight at Morgan Stanley
  • BGS: Warehousing Reports 5-Yr Logistics Services Pact
  • BHP: Downgraded at Deutsche Bank
  • BMI: Downgraded at Boenning & Scattergood
  • BMR: Sells King of Prussia Site for $35m
  • BMY: U.S. FDA Accepts Supplemental BLA for Opdivo+yervoy
  • BOOT: Agrees to Buy Sheplers for $147m Cash
  • BTU: Assumed Sell at Goldman
  • BX: TPG, Blackstone May Joint Bid for ANZ’s Esanda Unit: Australian
  • BYD: Upgraded at Credit Suisse
  • C: Upgraded at Goldman
  • CA: Cut to Sell at Citi
  • CALA: Drug Reduced Lesions in One TNBC Patient
  • CELG: To Reach 2020 Hematology, Oncology Targets
  • CIO: To Buy Office Property in Denver for $35M
  • CLDX: Rintega Shows Survival Benefit in Brain Cancer Study
  • COLL: New Buy at Jefferies, Needham, New Overweight at Piper Jaffray
  • CPTA: Files Mixed Securities Shelf
  • CRIS: CUDC-907 Has 2 Complete, 4 Partial Responses in DLBCL
  • CRM: Acquires Startup Tempo; No Terms
  • CTLT: Says Some Holders Offering to Sell 20M Shrs
  • CTRE: Files $500M Mixed Securities Shelf
  • CVX: To Sell NZ Stations to Z Energy for About NZ$800m: AFR
  • CY: Cypress Semiconductor Offers to Buy ISSI for $20.25-Shr Cash
  • DHI: Looks Like “Particularly Attractive Choice”: Barron’s
  • DIS: Shares Are Poised To Rise 50% Over Next 3 Yrs: Barron’s
  • DLTR: Dollar Tree to Sell 330 Family Dollar Stores to Sycamore
  • DORM: May Rise 50% To $70 Within 2 Yrs: Barron’s
  • DUK: Upgraded at Bernstein
  • ENB: Upgraded at Credit Suisse
  • ENBL: Says CEO Lynn Bourdon Resigns
  • ENDRQ: Starts Marketing Process for North Sea Assets
  • EQR: Registers 1.12m Shrs for Holders
  • ESGR: CPPIB to Buy 9.9% Stake in Enstar From First Reserve
  • ESRX: May Lose Contract If Anthem Buys Humana: Cowen
  • EVEP: New Equal-Weight at Morgan Stanley
  • FATE: New Outperform at Leerink
  • FB: EU’s Vestager Rejects Calls for Law on Google, Facebook: FAZ
  • FDO: Dollar Tree to Sell 330 Family Dollar Stores to Sycamore
  • FELP: Energy Assumed Buy at Goldman
  • FFIV: Cut to Neutral vs Buy at Citi
  • FFKT: Downgraded at KBW
  • FGP: To Buy Bridger Logistics for $837.5m
  • FRO: Upgraded at DNB Markets, Evercore ISI, Nordea
  • FTK: Names Robert M. Schmitz as CFO
  • GEVA: Alexion Sees Synageva Deal Closing in Mid 2015
  • GM: GM Korea’s Sales Grow 3.6% in May: Yonhap
  • GOOG: Seeks Dominance of All Internet Services, Gabriel Says
  • GORO: Works to Return to Normal Ops After ‘Illegal’ Mine Protest
  • GPOR: Upgraded at Wells Fargo
  • GSBD: Downgraded at Wells Fargo
  • GT: Sumitomo Rubber, Goodyear to End Alliance, Nikkei Says
  • HCN: Upgraded at Evercore ISI
  • HLT: Doubletree by Hilton Adds Hawaii Conversion to Global Pipeline
  • HNH: Handy & Harman to Pay $11/Shr Cash for Jps
  • HOG: Battery Powered Harley Motorcycle Seen Several Years Away: WSJ
  • HOLX: PT Raised to $40 From $37 at Canaccord
  • HRTX: Leerink boosted PT Late Friday; Entered Commercial Manufacturing Services Agreement With Lifecore Biomedical
  • HT: Reports 1-for-4 Reverse Shr Split
  • HUM: Removed From Best Ideas List at Wedbush
  • IGT: Announced Signing of Pact W/ MGC
  • INCY: Advaxis Says FDA OKs Phase 2 study of ADXS-HPV With Incyte Drug
  • INGR: Is “Hunting” For Opportunities To Buy $300M-$500M Size Cos., Says Ceo Gordon: Barron’s
  • INTC: Intel To Buy Altera For $54-Shr
  • ISSI: Cypress Semiconductor Offers to Buy ISSI for $20.25-Shr Cash
  • JASN: Buys Dronco, Boosts Yr Sales View on Deal
  • JPST: Handy & Harman to Pay $11/Shr Cash for Jps
  • KO: Upgraded at BMO Capital Markets
  • KPTI: Sees Partial Responses in Heavily Pretreated Patients
  • LINE: New Equal-Weight at Morgan Stanley
  • MAN: To Buy Greythorn’s Australian, Singapore Ops
  • MDCO: Presents Results of ABP-700 Phase 1 Study 0
  • MEMP: New Overweight at Morgan Stanley
  • MGNX: Reports More Tumor Shrinkage in Study
  • MGPI: Says CFO Don Tracy Left Company
  • MHR: Gets Extension From Lenders on Credit Pact
  • MNK: Orexigen in Pact for Mallinckrodt to Manufacture Naltrexone
  • MOH: Files Automatic Mixed Securities Shelf
  • MPO: Sees 2Q Production 33,000-34,000 BOE/D
  • MSFT: Says Windows 10 Available as Free Upgrade on July 29
  • MW: George Zimmer to Open ‘zTailors’ Mobile Tailor App: NYT
  • NES: Sees 2Q Rev. Down Mid- to Upper-Teens Q/q
  • NFX: Sees 2Q Production at Lower End of View on Flooding
  • NGL: Yr Adj Ebitda Up 64% Y/y to $443.3m
  • NORD: Education Files $500M Shelf for Ordinary Shares
  • NUE: May Rise 25% To $60: Barron’s
  • NVDA: Expects to Sell Hundreds of Millions of Shield Consoles
  • NWHM: Says John Stephens Will Assume Role of CFO
  • OII: Sees 2015 EPS Lower Than 2014 EPS
  • OREX: Orexigen in Pact for Mallinckrodt to Manufacture Naltrexone
  • ORLY: Boosts Buyback Authorization by $500m to $5.5b
  • OXY: Upgraded at Deutsche Bank
  • PAA: Installs New Section of Pipe After California Oil Spill
  • PAY: Upgraded at Raymond James
  • PBF: Delaware City Refinery Reports Leak in Unit Yday
  • PCAR: Upgraded at BMO Capital
  • PCTY: Downgraded at Raymond James
  • PIR: WSM Potential Buy of Pier 1 Accretive at $19/Shr, BB&T Says
  • POST: Upgraded at Wells Fargo
  • POZN: Names Adrian Adams as CEO; Plachetka Retires Immediately
  • RARE: Pharma Removed From Focus List at Robert Baird
  • RAVN: Unit Gets DOD Contract for Tethered Aerostat
  • REGI: Upgraded at Piper Jaffray
  • RELL: Reports Retirement of CFO
  • RMTI: Reports Triferic Gets Q-Code Assignment
  • RXDX: Phase 1 Trial Data for Entrectinib
  • RYAM: Borregaard, RYAM Enter Non-Binding 150,000t Lignin Plant Deal
  • SBLK: Upgraded at Deutsche Bank
  • SPB: Reinstated Buy at Deutsche Bank
  • SXC: Assumed Buy at Goldman
  • TAOM: Gets ‘Going Private’ Proposal at ~21% Premium
  • TCPC: Files $600M Mixed Securities Shelf
  • TEGP: New Buy at BofA, New Outperform at Credit Suisse, New Overweight at Barclays
  • TEP: New Outperform at RBC
  • TPH: Upgraded at FBR Capital
  • TRIV: Files $100M Mixed Securities Shelf
  • TSLA: Clean Energy Technology ‘Winners’ to Emerge Over 2-3 Yrs: Baird
  • TTMI: Completes Purchase of Viasystems Group
  • TWER: Files Mixed Securities Shelf
  • TWX: “San Andreas” Has $53.2 Mln as Weekend’s Top Film
  • TXTR: Shareholder Northwater Asks Board to Explore Options
  • TYPE: Downgraded at GARP Research
  • UPS: May Rise 20% To $119: Barron’s
  • USCR: Buys Dubrook Concrete in Virginia, No Terms
  • VNR: New Overweight at Morgan Stanley
  • WEX: Signs Over-the-Road Fuel Card Program With GE Capital
  • WPC: Two Carey Watermark Trusts Buy Hotel in JV With GB Key Biscayne
  • WSM: WSM Potential Buy of Pier 1 Accretive at $19/Shr, BB&T Says
  • XEL: Nsp-Wisconsin Seeks Overall Boost Yrly Electric Rates of $27.4M
  • XL: Resumed Neutral at JPMorgan, Previously Underweight
  • XPO: Said Seeking to Raise $3.26b to Fund Deals:Reuters
  • ZFC: Reports New CFO

To continue reading this article you must be a Bloomberg Professional Service Subscriber.